Highbridge Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Highbridge Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,603	Closed	-$82K	–	356
2018 Q4	$82K	Sell	2,603 -12,397	-83%	-$504K	﹤0.01%	345
2018 Q3	$908K	Sell	15,000 -151,199	-91%	-$8.49M	0.02%	398
2018 Q2	$8.81M	Sell	166,199 -43,801	-21%	-$2.63M	0.18%	161
2018 Q1	$12.2M	Sell	210,000 -20,000	-9%	-$1.25M	0.2%	116
2017 Q4	$8.05M	Buy	230,000 +226,683	+6,834%	+$7.46M	0.14%	195
2017 Q3	$121K	Hold	3,317	–	–	﹤0.01%	1465
2017 Q2	$83K	Hold	3,317	–	–	﹤0.01%	1175
2017 Q1	$90K	Hold	3,317	–	–	﹤0.01%	1384
2016 Q4	$96K	Buy	+3,317	New	+$108K	﹤0.01%	1196

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Highbridge Capital Management's ADVM Position: Q1 2019 in Review

Highbridge Capital Management sold out of Adverum Biotechnologies (ADVM) in Q1 2019, closing a stake of 2,603 shares — an estimated $82K sold.

Highbridge Capital Management first reported a position in ADVM in Q4 2016 and held it in 9 quarters. The position peaked at $12.2M in Q1 2018. 83 funds tracked by Wall St. Rank hold ADVM as of Q1 2019.

Highbridge Capital Management reported no remaining Adverum Biotechnologies position as of Q1 2019 after selling out during the quarter.
Highbridge Capital Management sold 2,603 Adverum Biotechnologies shares in Q1 2019, an estimated $82K.
Highbridge Capital Management first reported a position in Adverum Biotechnologies in Q4 2016 and held it in 9 quarters.
Highbridge Capital Management's Adverum Biotechnologies position peaked at $12.2M in Q1 2018.
83 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2019.

Based on Highbridge Capital Management's 13F filing for Q1 2019, filed 15 May 2019.